Gilead, Foster City, CA.
Novartis Institutes for BioMedical Research, Cambridge, MA.
Diabetes. 2020 May;69(5):1032-1041. doi: 10.2337/db19-0813. Epub 2020 Feb 20.
Type 2 diabetes (T2D) is caused by loss of pancreatic β-cell mass and failure of the remaining β-cells to deliver sufficient insulin to meet demand. β-Cell glucolipotoxicity (GLT), which refers to combined, deleterious effects of elevated glucose and fatty acid levels on β-cell function and survival, contributes to T2D-associated β-cell failure. Drugs and mechanisms that protect β-cells from GLT stress could potentially improve metabolic control in patients with T2D. In a phenotypic screen seeking low-molecular-weight compounds that protected β-cells from GLT, we identified compound A that selectively blocked GLT-induced apoptosis in rat insulinoma cells. Compound A and its optimized analogs also improved viability and function in primary rat and human islets under GLT. We discovered that compound A analogs decreased GLT-induced cytosolic calcium influx in islet cells, and all measured β-cell-protective effects correlated with this activity. Further studies revealed that the active compound from this series largely reversed GLT-induced global transcriptional changes. Our results suggest that taming cytosolic calcium overload in pancreatic islets can improve β-cell survival and function under GLT stress and thus could be an effective strategy for T2D treatment.
2 型糖尿病(T2D)是由胰岛β细胞数量减少和剩余β细胞无法分泌足够的胰岛素以满足需求引起的。β细胞糖脂毒性(GLT)是指升高的葡萄糖和脂肪酸水平对β细胞功能和存活的联合有害影响,导致与 T2D 相关的β细胞衰竭。能够保护β细胞免受 GLT 应激的药物和机制可能有助于改善 T2D 患者的代谢控制。在一项针对低分子量化合物的表型筛选中,这些化合物可保护β细胞免受 GLT 损伤,我们发现化合物 A 可选择性地阻止大鼠胰岛素瘤细胞中的 GLT 诱导的细胞凋亡。化合物 A 及其优化的类似物还改善了 GLT 下原代大鼠和人胰岛的活力和功能。我们发现化合物 A 类似物可减少胰岛细胞中 GLT 诱导的胞质钙内流,并且所有测量的β细胞保护作用都与该活性相关。进一步的研究表明,该系列中的活性化合物在很大程度上逆转了 GLT 诱导的全局转录变化。我们的研究结果表明,控制胰腺胰岛中的细胞溶质钙超载可以改善 GLT 应激下的β细胞存活和功能,因此可能是 T2D 治疗的有效策略。